Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2016

View Archived Issues

Bavarian Nordic collaborates with Evaxion Biotech and DTU to develop a novel MRSA vaccine

GlaxoSmithKline reviews milestones of fourth quarter 2015

Cue collaborates with Janssen on quantitative HIV viral load test

Riboxx Pharmaceuticals and Tollys enter agreement for new drug development program

Vertical Pharmaceuticals, Trigen and Osmotica form combined company

Cancer Research UK begins phase I study of taladegib

Zepatier approved in Canada for the treatment of chronic HCV genotypes 1, 3 or 4

Avita Medical completes sale of its respiratory business

Amarantus requests FDA rare pediatric disease designation for MANF

Ember Therapeutics completes reverse merger with American Home Alliance

FDA issues complete response letter to Vertex for Kalydeco sNDA

Pfizer discloses phosphodiesterase 4B inhibitors

ViiV Healthcare patents compounds to treat HIV infection

Aurigene Discovery Technologies reports Nampt inhibitors

Bayer Schering Pharma presents antimitotic drugs

Takeda reviews highlights of third quarter of fiscal 2015

FDA awards breakthrough therapy designation to IMMU-132 for triple-negative breast cancer

Recombinant factor VIII exhibits promising profile for the treatment of hemophilia A

Long-acting FVIIa shows promise for the treatment of hemophilia

Microbix Biosystems to develop products to combat Zika virus

Muscular Dystrophy Association to collaborate in MoveDMD trial

Atlas Genetics' Chlamydia diagnostic receives E.U. approval

FDA places partial clinical hold on pacritinib

EBV-CTL granted U.S. orphan status for EBV-positive post-transplant lymphoproliferative disorders

EMA confirms positive risk-benefit ratio of Xarelto for prevention of stroke in patients with AF